OTC Misfire Salvaged As Rx Prospect: Barrier Touts Antifungal Zimycan Trial
This article was originally published in The Tan Sheet
Executive Summary
Barrier Therapeutics plans to parlay Johnson & Johnson's failed over-the-counter diaper cream Zimycan into the first prescription treatment for diaper rash complicated by Candida yeast infection